Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 24, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	8	82	45	23	377	819
Market Cap Growth	-88.30%	82.80%	95.46%	-93.89%	-53.99%	-45.64%
Enterprise Value	-1	50	-38	-71	264	682
Last Close Price	0.14	1.87	1.05	0.64	12.62	27.78
PB Ratio	7.05	2.73	0.53	0.23	3.18	4.76
P/TBV Ratio	12.80	-	11.89	0.24	3.18	4.76
Debt / Equity Ratio	16.99	0.49	0.16	0.01	0.01	0.00
Net Debt / Equity Ratio	-7.83	-0.86	-0.72	-0.89	-0.89	-0.77
Net Debt / EBITDA Ratio	0.20	0.78	2.52	1.80	1.17	1.70
Net Debt / FCF Ratio	0.21	0.81	3.32	2.03	1.67	2.62
Quick Ratio	1.05	5.73	7.95	29.71	7.59	7.87
Current Ratio	1.12	6.05	8.09	30.55	7.85	8.11
Return on Equity (ROE)	-247.78%	-98.63%	-33.81%	-47.14%	-61.85%	-53.42%
Return on Assets (ROA)	-22.10%	-14.90%	-11.33%	-26.40%	-34.99%	-31.42%
Return on Capital Employed (ROCE)	-49.90%	-31.40%	-15.60%	-49.70%	-75.90%	-45.70%
Earnings Yield	-746.94%	-69.06%	-69.73%	-224.32%	-23.86%	-9.38%
FCF Yield	-510.95%	-39.09%	-40.99%	-191.80%	-16.74%	-6.21%
Buyback Yield / Dilution	-10.61%	-16.18%	-11.17%	-12.71%	-1.86%	-53.30%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q